Xinxia Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Xinxia Li has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Wei Zhang
Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region 830054, P.R. China
8 shared publicationsJing Niu
Department of Pathology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
5 shared publicationsRan Zhang
Department of Pathology, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, 830000, Xinjiang, China
5 shared publicationsCancan Wang
Department of Pathology, Xinjiang Medical University Affiliated Tumor Hospital, Urumqi, 830000, Xinjiang, China
4 shared publications- Hai-Xia Gao
Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, No. 137 Liyushan Southern Road, Urumqi, The Xinjiang Uygur Autonomous Region of China, 830054, PR China; Xinjiang Medical University, No. 393 Xinyi Road, Urumqi, The Xinjiang Uygur Autonomous Region of China, 830011, PR China
4 shared publications - Shufang Yan
Department of Critical Care Medicine of Karamay Central Hospital, No. 67, Junggar Road, Karamay Region, Karamay, Xinjiang Uygur Autonomous Region 834000, China
4 shared publications
Latest Publications
- Open Access
- 13 June 2026
- Published byΒ Springer NatureΒ inΒ Scientific Reports
- Vol.Β 16 Β (1)
SPP1-positive myeloid cell subpopulations associated with resistance to PD-1/L1 immunotherapy in lung adenocarcinoma
PD-1/PD-L1 immune checkpoint inhibitors have significantly improved outcomes in Lung adenocarcinoma (LUAD), yet many patients remain unresponsive due to resistance. This study aimed to identify key cellular subpopulations associated with immunotherapy resistance in LUAD. Clinical data from 197 LUAD patients treated with PD-1/PD-L1 inhibitors were retrospectively analyzed, including 79 with response and 118 with resistance. Fresh tumor tissues from three patients per group underwent single-cell RNA sequencing (scRNA-seq), and one sample per group was analyzed using spatial transcriptomics. Immunohistochemistry (IHC) and immunofluorescence (IF) were used to validate protein expression and overlapping spatial signals. scRNA-seq revealed a distinct SPP1βΊ myeloid subpopulation enriched in resistant tumors. Pseudotime analysis suggested these cells are in a differentiation state linked to tumor progression. SCENIC analysis indicated activation of transcriptional networks potentially contributes to immune suppression. Spatial transcriptomics confirmed SPP1βΊ myeloid cells were localized near tumor nests in resistant tissues, suggesting an association with immunosuppressive microenvironment. IHC and IF further validated increased SPP1 expression and its overlapping spatial signals with macrophage markers CD68 and CD163, confirming their tumor-associated macrophage identity. This study identifies SPP1βΊ myeloid cells as a subpopulation closely associated with LUAD immunotherapy resistance. They may serve as a potential candidate biomarker for predicting PD-1/PD-L1 treatment outcomes and represent targets for further functional exploration.
- 13 June 2026
- Published byΒ Springer NatureΒ inΒ Scientific Reports
- Vol.Β 16 Β (1)
Open AccessSPP1-positive myeloid cell subpopulations associated with resistance to PD-1/L1 immunotherapy in lung adenocarcinoma
PD-1/PD-L1 immune checkpoint inhibitors have significantly improved outcomes in Lung adenocarcinoma (LUAD), yet many patients remain unresponsive due to resistance. This study aimed to identify key cellular subpopulations associated with immunotherapy resistance in LUAD. Clinical data from 197 LUAD patients treated with PD-1/PD-L1 inhibitors were retrospectively analyzed, including 79 with response and 118 with resistance. Fresh tumor tissues from three patients per group underwent single-cell RNA sequencing (scRNA-seq), and one sample per group was analyzed using spatial transcriptomics. Immunohistochemistry (IHC) and immunofluorescence (IF) were used to validate protein expression and overlapping spatial signals. scRNA-seq revealed a distinct SPP1βΊ myeloid subpopulation enriched in resistant tumors. Pseudotime analysis suggested these cells are in a differentiation state linked to tumor progression. SCENIC analysis indicated activation of transcriptional networks potentially contributes to immune suppression. Spatial transcriptomics confirmed SPP1βΊ myeloid cells were localized near tumor nests in resistant tissues, suggesting an association with immunosuppressive microenvironment. IHC and IF further validated increased SPP1 expression and its overlapping spatial signals with macrophage markers CD68 and CD163, confirming their tumor-associated macrophage identity. This study identifies SPP1βΊ myeloid cells as a subpopulation closely associated with LUAD immunotherapy resistance. They may serve as a potential candidate biomarker for predicting PD-1/PD-L1 treatment outcomes and represent targets for further functional exploration.
- Open Access
- 22 July 2025
- Published byΒ Springer NatureΒ inΒ Journal of Translational Medicine
- Vol.Β 23 Β (1) , 1-12
miR-193a-3p prevents tumour progression by targeting TCL1 in diffuse large B-cell lymphoma
Both miR-193a-3p and T-Cell Leukemia/Lymphoma 1 (TCL1) are enriched in the PI3K/AKT signaling pathway, which is pivotal for the regulation of the initiation and progression of diffuse large B-cell lymphoma (DLBCL). Although miR-193a-3p has been demonstrated to exert an inhibitory effect in various tumors, the relationship between miR-193a-3p and TCL1, as well as the mechanisms by which miR-193a-3p participates in the modulation of DLBCL onset and progression, remain to be elucidated. The expression levels of miR-193a-3p and TCL1 in DLBCL cells were examined using quantitative real-time polymerase chain reaction (qRT-PCR), and their impact on DLBCL cell growth was assessed through cell proliferation assays and flow cytometry. Subsequently, the interaction between miR-193a-3p and TCL1 was investigated using a dual-luciferase reporter assay. A nude mouse model of subcutaneous DLBCL was established in which the mice were injected with miR-193a-3p agomir, and were evaluated after 45 days. Finally, the mechanism by which miR-193a-3p modulates the PI3K/AKT signaling pathway was explored via qRT-PCR and Western blotting analyses. It was found that miR-193a-3p is downregulated, while TCL1 is upregulated in DLBCL. miR-193a-3p was shown to inhibit proliferation and induce apoptosis in DLBCL cells, in contrast to TCL1, which promotes proliferation and suppresses apoptosis. Moreover, TCL1 was identified as a target gene of miR-193a-3p. Additionally, it was demonstrated that miR-193a-3p regulates the PI3K/AKT signaling pathway through TCL1 both in vitro and in vivo. Collectively, these findings indicate that miR-193a-3p suppresses the growth of DLBCL by targeting TCL1 within the PI3K/AKT signaling pathway.
- 22 July 2025
- Published byΒ Springer NatureΒ inΒ Journal of Translational Medicine
- Vol.Β 23 Β (1) , 1-12
Open AccessmiR-193a-3p prevents tumour progression by targeting TCL1 in diffuse large B-cell lymphoma
Both miR-193a-3p and T-Cell Leukemia/Lymphoma 1 (TCL1) are enriched in the PI3K/AKT signaling pathway, which is pivotal for the regulation of the initiation and progression of diffuse large B-cell lymphoma (DLBCL). Although miR-193a-3p has been demonstrated to exert an inhibitory effect in various tumors, the relationship between miR-193a-3p and TCL1, as well as the mechanisms by which miR-193a-3p participates in the modulation of DLBCL onset and progression, remain to be elucidated. The expression levels of miR-193a-3p and TCL1 in DLBCL cells were examined using quantitative real-time polymerase chain reaction (qRT-PCR), and their impact on DLBCL cell growth was assessed through cell proliferation assays and flow cytometry. Subsequently, the interaction between miR-193a-3p and TCL1 was investigated using a dual-luciferase reporter assay. A nude mouse model of subcutaneous DLBCL was established in which the mice were injected with miR-193a-3p agomir, and were evaluated after 45 days. Finally, the mechanism by which miR-193a-3p modulates the PI3K/AKT signaling pathway was explored via qRT-PCR and Western blotting analyses. It was found that miR-193a-3p is downregulated, while TCL1 is upregulated in DLBCL. miR-193a-3p was shown to inhibit proliferation and induce apoptosis in DLBCL cells, in contrast to TCL1, which promotes proliferation and suppresses apoptosis. Moreover, TCL1 was identified as a target gene of miR-193a-3p. Additionally, it was demonstrated that miR-193a-3p regulates the PI3K/AKT signaling pathway through TCL1 both in vitro and in vivo. Collectively, these findings indicate that miR-193a-3p suppresses the growth of DLBCL by targeting TCL1 within the PI3K/AKT signaling pathway.
- Open Access
- 4 July 2025
- Published byΒ Springer NatureΒ inΒ Scientific Reports
- Vol.Β 15 Β (1) , 1-17
Multi-omics and experimental validation reveal mechanism of compound mylabris capsules in treating diffuse large B-cell lymphoma
Compound mylabris capsules (CMC) are widely used in the treatment of various malignant tumors; however, their mechanisms of action in diffuse large B-cell lymphoma (DLBCL) remain poorly understood. To address this, we analyzed DLBCL-related datasets from GEO and TCGA, identifying 943 key genes through differential expression gene analysis and weighted gene co-expression network analysis. By constructing a drug-active ingredient-target network, we determined the top five active CMC ingredients and their associated 1053 gene targets. Intersection analysis between CMC targets and key DLBCL genes revealed 50 overlapping targets. Enrichment analysis highlighted critical pathways, including the cell cycle and p53 signaling. Single-cell RNA sequencing further demonstrated that these targets are predominantly expressed in DLBCL tumor cell subsets. Protein-protein interaction network analysis identified pivotal genes such as CDK1 and CDK2, which showed robust diagnostic and prognostic value, as confirmed by receiver operating characteristic and survival analyses. Molecular docking and dynamics simulations validated the high binding affinity of sitosterol (a primary CMC component) to these targets. In vitro experiments demonstrated that sitosterol significantly inhibits DLBCL cell proliferation and induces apoptosis. In conclusion, our study elucidates the anti-tumor effects of CMC (mainly sitosterol) in DLBCL, mediated through the regulation of targets like CDK1 and CDK2. These findings provide critical evidence supporting the therapeutic potential of CMC in DLBCL treatment.
- 4 July 2025
- Published byΒ Springer NatureΒ inΒ Scientific Reports
- Vol.Β 15 Β (1) , 1-17
Open AccessMulti-omics and experimental validation reveal mechanism of compound mylabris capsules in treating diffuse large B-cell lymphoma
Compound mylabris capsules (CMC) are widely used in the treatment of various malignant tumors; however, their mechanisms of action in diffuse large B-cell lymphoma (DLBCL) remain poorly understood. To address this, we analyzed DLBCL-related datasets from GEO and TCGA, identifying 943 key genes through differential expression gene analysis and weighted gene co-expression network analysis. By constructing a drug-active ingredient-target network, we determined the top five active CMC ingredients and their associated 1053 gene targets. Intersection analysis between CMC targets and key DLBCL genes revealed 50 overlapping targets. Enrichment analysis highlighted critical pathways, including the cell cycle and p53 signaling. Single-cell RNA sequencing further demonstrated that these targets are predominantly expressed in DLBCL tumor cell subsets. Protein-protein interaction network analysis identified pivotal genes such as CDK1 and CDK2, which showed robust diagnostic and prognostic value, as confirmed by receiver operating characteristic and survival analyses. Molecular docking and dynamics simulations validated the high binding affinity of sitosterol (a primary CMC component) to these targets. In vitro experiments demonstrated that sitosterol significantly inhibits DLBCL cell proliferation and induces apoptosis. In conclusion, our study elucidates the anti-tumor effects of CMC (mainly sitosterol) in DLBCL, mediated through the regulation of targets like CDK1 and CDK2. These findings provide critical evidence supporting the therapeutic potential of CMC in DLBCL treatment.
- Open Access
- 13 November 2024
- Published byΒ Springer NatureΒ inΒ Molecular Medicine
- Vol.Β 30 Β (1) , 1-12
Lipid metabolism-related gene signature predicts prognosis and unveils novel anti-tumor drugs in specific type of diffuse large B cell lymphoma
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma which possess highly aggressive and heterogeneous. Despite advances in understanding heterogeneity and development of novel targeted agents, the prognosis of DLBCL patients remains unsatisfied. Lipids are crucial components of biological membranes and signal transduction while accumulating evidence has supported the vital roles of abnormal lipid metabolism in tumorigenesis. Furthermore, some related pathways could serve as prognostic biomarkers and potential therapeutic targets. However, the clinical significance of abnormal lipid metabolism reprogramming in DLBCL has not been investigated. In the current study, we developed a prognostic risk model for DLBCL based on the abnormal expressed lipid metabolism genes and moreover based on our risk model we classified patients with DLBCL into novel subtypes and identified potential drugs for DLBCL patients with certain lipid metabolism profiles. Methods: We utilized univariate Cox regression analysis to identify the prognosis-related lipid metabolism genes, and then performed LASSO Cox regression to identify prognostic related lipid metabolism related genes. Multivariate cox regression was used to establish the prognostic model. Patients were divided in to high and low risk groups based on the median risk score. Immune cell infiltration and GSEA were used to identify the pathways between high and low risk groups. Oncopredict algorithm was utilized to identify potential drug for high-risk patients. In vitro cell apoptosis and viability analysis were employed to verify the specific tumor inhibition effects of AZD5153. Results: Nineteen survival related lipid metabolism genes TMEM176B, LAYN, RAB6B, MMP9, ATAD3B, SLC2A11, CD3E, SLIT2, SLC2A13, SLC43A3, CD6, SIRPG, NEK6, LCP2, CTTN, CXCL2, SNX22, BCL6 and FABP4 were identified and subjected to build the prognostic model which was further verified in four external microarray cohorts and one RNA seq cohorts. Tumor immune microenvironment analysis and GSEA results showed that the activation of MYC targets genes rather than immunosuppression contribute to the poor survival outcome of patients in the high-risk group. AZD5153, a novel bivalent BET bromodomain inhibitor which could inhibit the transcription of MYC and E2F exhibited specific antitumor function for cells with high-risk score. Conclusions: Our results provide the first lipid metabolism-based gene signature for predicting the survival of patients with DLBCL. Furthermore, by determining novel subtypes with our lipid metabolism prognostic model we illustrated that drugs that compromising MYC target genes rather than immune checkpoint inhibitors may be beneficial to DLBCL patients with certain lipid metabolism profiles.
- 13 November 2024
- Published byΒ Springer NatureΒ inΒ Molecular Medicine
- Vol.Β 30 Β (1) , 1-12
Open AccessLipid metabolism-related gene signature predicts prognosis and unveils novel anti-tumor drugs in specific type of diffuse large B cell lymphoma
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma which possess highly aggressive and heterogeneous. Despite advances in understanding heterogeneity and development of novel targeted agents, the prognosis of DLBCL patients remains unsatisfied. Lipids are crucial components of biological membranes and signal transduction while accumulating evidence has supported the vital roles of abnormal lipid metabolism in tumorigenesis. Furthermore, some related pathways could serve as prognostic biomarkers and potential therapeutic targets. However, the clinical significance of abnormal lipid metabolism reprogramming in DLBCL has not been investigated. In the current study, we developed a prognostic risk model for DLBCL based on the abnormal expressed lipid metabolism genes and moreover based on our risk model we classified patients with DLBCL into novel subtypes and identified potential drugs for DLBCL patients with certain lipid metabolism profiles. Methods: We utilized univariate Cox regression analysis to identify the prognosis-related lipid metabolism genes, and then performed LASSO Cox regression to identify prognostic related lipid metabolism related genes. Multivariate cox regression was used to establish the prognostic model. Patients were divided in to high and low risk groups based on the median risk score. Immune cell infiltration and GSEA were used to identify the pathways between high and low risk groups. Oncopredict algorithm was utilized to identify potential drug for high-risk patients. In vitro cell apoptosis and viability analysis were employed to verify the specific tumor inhibition effects of AZD5153. Results: Nineteen survival related lipid metabolism genes TMEM176B, LAYN, RAB6B, MMP9, ATAD3B, SLC2A11, CD3E, SLIT2, SLC2A13, SLC43A3, CD6, SIRPG, NEK6, LCP2, CTTN, CXCL2, SNX22, BCL6 and FABP4 were identified and subjected to build the prognostic model which was further verified in four external microarray cohorts and one RNA seq cohorts. Tumor immune microenvironment analysis and GSEA results showed that the activation of MYC targets genes rather than immunosuppression contribute to the poor survival outcome of patients in the high-risk group. AZD5153, a novel bivalent BET bromodomain inhibitor which could inhibit the transcription of MYC and E2F exhibited specific antitumor function for cells with high-risk score. Conclusions: Our results provide the first lipid metabolism-based gene signature for predicting the survival of patients with DLBCL. Furthermore, by determining novel subtypes with our lipid metabolism prognostic model we illustrated that drugs that compromising MYC target genes rather than immune checkpoint inhibitors may be beneficial to DLBCL patients with certain lipid metabolism profiles.
- Open Access
- 10 November 2024
- Published byΒ ElsevierΒ inΒ Pathology - Research and Practice
- Vol.Β 264, 155720
Correlation between immune microenvironment and clinicopathological characteristics and prognosis of primary large B-cell lymphoma of immune-privileged sites
- 10 November 2024
- Published byΒ ElsevierΒ inΒ Pathology - Research and Practice
- Vol.Β 264, 155720
Open AccessCorrelation between immune microenvironment and clinicopathological characteristics and prognosis of primary large B-cell lymphoma of immune-privileged sites
- Open Access
- 8 February 2023
- Published byΒ Frontiers Media SAΒ inΒ Frontiers in Immunology
- Vol.Β 14, 1135930
Vitamin D3 alleviates inflammation in ulcerative colitis by activating the VDR-NLRP6 signaling pathway
Inflammation is a key factor in the development of ulcerative colitis (UC). 1,25-dihydroxyvitamin D3 (1,25(OH)2D3, VD3), as the major active ingredient of vitamin D and an anti-inflammatory activator, is closely related to the initiation and development of UC, but its regulatory mechanism remains unclear. In this study, we carried out histological and physiological analyses in UC patients and UC mice. RNA sequencing (RNA-seq), assays for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq), chromatin immunoprecipitation (ChIP) assays and protein and mRNA expression were performed to analyze and identify the potential molecular mechanism in UC mice and lipopolysaccharide (LPS)-induced mouse intestinal epithelial cells (MIECs). Moreover, we established nucleotide-binding oligomerization domain (NOD)-like receptor protein nlrp6-/- mice and siRNA-NLRP6 MIECs to further characterize the role of NLRP6 in anti-inflammation of VD3. Our study revealed that VD3 abolished NOD-like receptor protein 6 (NLRP6) inflammasome activation, suppressing NLRP6, apoptosis-associated speck-like protein (ASC) and Caspase-1 levels via the vitamin D receptor (VDR). ChIP and ATAC-seq showed that VDR transcriptionally repressed NLRP6 by binding to vitamin D response elements (VDREs) in the promoter of NLRP6, impairing UC development. Importantly, VD3 had both preventive and therapeutic effects on the UC mouse model via inhibition of NLRP6 inflammasome activation. Our results demonstrated that VD3 substantially represses inflammation and the development of UC in vivo. These findings reveal a new mechanism by which VD3 affects inflammation in UC by regulating the expression of NLRP6 and show the potential clinical use of VD3 in autoimmune syndromes or other NLRP6 inflammasome-driven inflammatory diseases.
- 8 February 2023
- Published byΒ Frontiers Media SAΒ inΒ Frontiers in Immunology
- Vol.Β 14, 1135930
Open AccessVitamin D3 alleviates inflammation in ulcerative colitis by activating the VDR-NLRP6 signaling pathway
Inflammation is a key factor in the development of ulcerative colitis (UC). 1,25-dihydroxyvitamin D3 (1,25(OH)2D3, VD3), as the major active ingredient of vitamin D and an anti-inflammatory activator, is closely related to the initiation and development of UC, but its regulatory mechanism remains unclear. In this study, we carried out histological and physiological analyses in UC patients and UC mice. RNA sequencing (RNA-seq), assays for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq), chromatin immunoprecipitation (ChIP) assays and protein and mRNA expression were performed to analyze and identify the potential molecular mechanism in UC mice and lipopolysaccharide (LPS)-induced mouse intestinal epithelial cells (MIECs). Moreover, we established nucleotide-binding oligomerization domain (NOD)-like receptor protein nlrp6-/- mice and siRNA-NLRP6 MIECs to further characterize the role of NLRP6 in anti-inflammation of VD3. Our study revealed that VD3 abolished NOD-like receptor protein 6 (NLRP6) inflammasome activation, suppressing NLRP6, apoptosis-associated speck-like protein (ASC) and Caspase-1 levels via the vitamin D receptor (VDR). ChIP and ATAC-seq showed that VDR transcriptionally repressed NLRP6 by binding to vitamin D response elements (VDREs) in the promoter of NLRP6, impairing UC development. Importantly, VD3 had both preventive and therapeutic effects on the UC mouse model via inhibition of NLRP6 inflammasome activation. Our results demonstrated that VD3 substantially represses inflammation and the development of UC in vivo. These findings reveal a new mechanism by which VD3 affects inflammation in UC by regulating the expression of NLRP6 and show the potential clinical use of VD3 in autoimmune syndromes or other NLRP6 inflammasome-driven inflammatory diseases.
- Open Access
- 28 September 2022
- Published byΒ WileyΒ inΒ Journal of Immunology Research
- Vol.Β 2022, 1-18
Expression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common pathological subtype of non-Hodgkin lymphoma (NHL) and is the most common type of adult lymphoma. Due to the poor prognosis of relapsed/refractory DLBCL, new drug targets and therapeutic methods are urgently needed. We investigated the expression of programmed death ligand 1 (PD-L1) and 3-monooxygenase/tryptophan 5-monooxygenase activating protein zeta (14-3-3ΞΆ or YWHAZ) in patients with DLBCL. The purpose was to verify the expression levels of YWHAZ and PD-L1 and their relationships with the prognosis of DLBCL and to lay a foundation for further study on the role of YWHAZ and PD-L1 in DLBCL. Immunohistochemistry was used in 140 patients with DLBCL to test protein expression levels of YWHAZ and PD-L1. All patients were followed up in the hospital or by telephone or via WeChat. The positive expression rate of YWHAZ was 62.14% (87/140). The expression was negatively correlated with the positive expression of BAD ( , ) and positively correlated with the positive expression of BCL-2 ( , ). When the cut-off value for PD-L1 was established at 5%, 10%, 15%, and 20%, the corresponding positive expression rates of PD-L1 were 79.66% (94/118), 51.69% (61/118), 40.68% (48/118), and 36.44% (43/118). YWHAZ significantly affected the OS of DLBCL ( ). The prognosis of the patients was related to the positive expression of PD-L1 when the cut-off value of PD-L1 was 5% ( ). However, positive expression of PD-L1 was not associated with the prognosis when the cut-off values of PD-L1 were 10% ( ), 15% ( ), and 20% ( ). The positive expression of YWHAZ (hazard ratio 6.215; 95% confidence interval 3.214-12.017; ) was an independent adverse prognostic factor for OS. YWHAZ may be an important oncogene in the occurrence and development of DLBCL and may be used as a therapeutic target. PD-L1 may be an oncogene or tumor suppressor gene in the occurrence and development of DLBCL. Different cut-off values of PD-L1 may affect the prognosis of DLBCL.
- 28 September 2022
- Published byΒ WileyΒ inΒ Journal of Immunology Research
- Vol.Β 2022, 1-18
Open AccessExpression of PD-L1 and YWHAZ in Patients with Diffuse Large B Cell Lymphoma: A Possible Association with the Prognosis of Lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common pathological subtype of non-Hodgkin lymphoma (NHL) and is the most common type of adult lymphoma. Due to the poor prognosis of relapsed/refractory DLBCL, new drug targets and therapeutic methods are urgently needed. We investigated the expression of programmed death ligand 1 (PD-L1) and 3-monooxygenase/tryptophan 5-monooxygenase activating protein zeta (14-3-3ΞΆ or YWHAZ) in patients with DLBCL. The purpose was to verify the expression levels of YWHAZ and PD-L1 and their relationships with the prognosis of DLBCL and to lay a foundation for further study on the role of YWHAZ and PD-L1 in DLBCL. Immunohistochemistry was used in 140 patients with DLBCL to test protein expression levels of YWHAZ and PD-L1. All patients were followed up in the hospital or by telephone or via WeChat. The positive expression rate of YWHAZ was 62.14% (87/140). The expression was negatively correlated with the positive expression of BAD ( , ) and positively correlated with the positive expression of BCL-2 ( , ). When the cut-off value for PD-L1 was established at 5%, 10%, 15%, and 20%, the corresponding positive expression rates of PD-L1 were 79.66% (94/118), 51.69% (61/118), 40.68% (48/118), and 36.44% (43/118). YWHAZ significantly affected the OS of DLBCL ( ). The prognosis of the patients was related to the positive expression of PD-L1 when the cut-off value of PD-L1 was 5% ( ). However, positive expression of PD-L1 was not associated with the prognosis when the cut-off values of PD-L1 were 10% ( ), 15% ( ), and 20% ( ). The positive expression of YWHAZ (hazard ratio 6.215; 95% confidence interval 3.214-12.017; ) was an independent adverse prognostic factor for OS. YWHAZ may be an important oncogene in the occurrence and development of DLBCL and may be used as a therapeutic target. PD-L1 may be an oncogene or tumor suppressor gene in the occurrence and development of DLBCL. Different cut-off values of PD-L1 may affect the prognosis of DLBCL.
- Open Access
- 13 July 2022
- Published byΒ WileyΒ inΒ Evidence-Based Complementary and Alternative Medicine
- Vol.Β 2022, 1-14
Effects of hsa-miR-28-5p on Adriamycin Sensitivity in Diffuse Large B-Cell Lymphoma
Background. Adriamycin (doxorubicin) is an important traditional drug that exhibits cytotoxicity in Diffuse Large B-cell Lymphoma (DLBCL). Doxorubicin affects the DLBCL cells at all stages of their cell cycle. Combined with our previous results, this study discovered that the overexpression of hsa-miR-28-5p inhibited the proliferation, promoted apoptosis, and triggered cell cycle arrest at the S-phase in DLBCL cells. However, the effect of (Homo sapiens, hsa)-microRNA (miR)-28-5p on doxorubicin sensitivity in DLBCL has not been investigated. This study aims to reveal the effects of hsa-miR-28-5p on doxorubicin sensitivity at the level of DLBCL cells. Methods. To determine the optimal concentration of doxorubicin, different concentrations of doxorubicin were used to treat DLBCL cells. CCK-8 assay was used to detect the proliferation of DLBCL cells. The hsa-miR-28-5p-mimic NC and hsa-miR-28-5p mimic were transfected to doxorubicin-mediated DLBCL cells. Simultaneously, blank control groups were set up. The cells were cultured and transfected for 24h. Next, each group was administered with different concentrations of doxorubicin and cultured again for 24h to observe the effects of hsa-miR-28-5p on doxorubicin sensitivity at different times. The proliferation, early apoptosis, and late apoptosis in DLBCL cells were determined using soft agar colony-forming assay, mitochondrial membrane potential assay, and caspase-3 activity assay, respectively. The apoptosis and cell cycle were explored using Annexin V-PE/7-AAD and PI/RNase staining buffer, respectively. We speculated that PD-L1 might be involved in the effect of hsa-miR-28-5p on the sensitivity of adriamycin (doxorubicin) in the DLBCL cells. Hence, we performed immunohistochemistry (IHC) to determine PD-L1 expression within formalin-fixed paraffin-embedded (FFPE) samples from 52 DLBCL cases. Results. The optimal concentration of doxorubicin targeting DLBCL cells was found to be 3.028ΞΌmol/l. The effect of doxorubicin on DLBCL cells was time- and concentration-dependent. hsa-miR-28-5p mimic+doxorubicin remarkably decreased proliferation of DLBCL. DLBCL cell apoptosis rate was the highest in hsa-miR-28-5p mimic+doxorubicin group. Apart from that, hsa-miR-28-5p mimic plus doxorubicin had the best effect in promoting DLBCL cell apoptosis. After the intervention of hsa-miR-28-5p mimic+doxorubicin on DLBCL cells, the cell cycle was arrested in the S-phase and DNA synthesis was blocked. hsa-miR-28-5p mimic+doxorubicin could regulate the cycle of DLBCL cells. As a result, overexpression of hsa-miR-28-5p combined with doxorubicin is possibly involved in the development of DLBCL by affecting the proliferation, apoptosis, and cycle of DLBCL cells. PD-L1 showed an association with the prognosis of DLBCL patients. Combining with the literature, this suggested hsa-miR-28-5p may influence DLBCL occurrence and therapeutic effect by regulating the PD-L1 level. Conclusion. The combination of hsa-miR-28-5p mimic and doxorubicin may be considered more effective in inhibiting growth, arresting the cell cycle, and promoting cell apoptosis of DLBCL cells compared to using doxorubicin alone. The effects of doxorubicin on DLBCL cells were found to be time- and concentration-dependent. The overexpression of hsa-miR-28-5p enhanced the effect of doxorubicin on DLBCL cells, which may be attributed to the regulation of PD-L1 levels.
- 13 July 2022
- Published byΒ WileyΒ inΒ Evidence-Based Complementary and Alternative Medicine
- Vol.Β 2022, 1-14
Open AccessEffects of hsa-miR-28-5p on Adriamycin Sensitivity in Diffuse Large B-Cell Lymphoma
Background. Adriamycin (doxorubicin) is an important traditional drug that exhibits cytotoxicity in Diffuse Large B-cell Lymphoma (DLBCL). Doxorubicin affects the DLBCL cells at all stages of their cell cycle. Combined with our previous results, this study discovered that the overexpression of hsa-miR-28-5p inhibited the proliferation, promoted apoptosis, and triggered cell cycle arrest at the S-phase in DLBCL cells. However, the effect of (Homo sapiens, hsa)-microRNA (miR)-28-5p on doxorubicin sensitivity in DLBCL has not been investigated. This study aims to reveal the effects of hsa-miR-28-5p on doxorubicin sensitivity at the level of DLBCL cells. Methods. To determine the optimal concentration of doxorubicin, different concentrations of doxorubicin were used to treat DLBCL cells. CCK-8 assay was used to detect the proliferation of DLBCL cells. The hsa-miR-28-5p-mimic NC and hsa-miR-28-5p mimic were transfected to doxorubicin-mediated DLBCL cells. Simultaneously, blank control groups were set up. The cells were cultured and transfected for 24h. Next, each group was administered with different concentrations of doxorubicin and cultured again for 24h to observe the effects of hsa-miR-28-5p on doxorubicin sensitivity at different times. The proliferation, early apoptosis, and late apoptosis in DLBCL cells were determined using soft agar colony-forming assay, mitochondrial membrane potential assay, and caspase-3 activity assay, respectively. The apoptosis and cell cycle were explored using Annexin V-PE/7-AAD and PI/RNase staining buffer, respectively. We speculated that PD-L1 might be involved in the effect of hsa-miR-28-5p on the sensitivity of adriamycin (doxorubicin) in the DLBCL cells. Hence, we performed immunohistochemistry (IHC) to determine PD-L1 expression within formalin-fixed paraffin-embedded (FFPE) samples from 52 DLBCL cases. Results. The optimal concentration of doxorubicin targeting DLBCL cells was found to be 3.028ΞΌmol/l. The effect of doxorubicin on DLBCL cells was time- and concentration-dependent. hsa-miR-28-5p mimic+doxorubicin remarkably decreased proliferation of DLBCL. DLBCL cell apoptosis rate was the highest in hsa-miR-28-5p mimic+doxorubicin group. Apart from that, hsa-miR-28-5p mimic plus doxorubicin had the best effect in promoting DLBCL cell apoptosis. After the intervention of hsa-miR-28-5p mimic+doxorubicin on DLBCL cells, the cell cycle was arrested in the S-phase and DNA synthesis was blocked. hsa-miR-28-5p mimic+doxorubicin could regulate the cycle of DLBCL cells. As a result, overexpression of hsa-miR-28-5p combined with doxorubicin is possibly involved in the development of DLBCL by affecting the proliferation, apoptosis, and cycle of DLBCL cells. PD-L1 showed an association with the prognosis of DLBCL patients. Combining with the literature, this suggested hsa-miR-28-5p may influence DLBCL occurrence and therapeutic effect by regulating the PD-L1 level. Conclusion. The combination of hsa-miR-28-5p mimic and doxorubicin may be considered more effective in inhibiting growth, arresting the cell cycle, and promoting cell apoptosis of DLBCL cells compared to using doxorubicin alone. The effects of doxorubicin on DLBCL cells were found to be time- and concentration-dependent. The overexpression of hsa-miR-28-5p enhanced the effect of doxorubicin on DLBCL cells, which may be attributed to the regulation of PD-L1 levels.
- Open Access
- 22 February 2022
- Published byΒ WileyΒ inΒ Analytical Cellular Pathology
- Vol.Β 2022, 1-13
Analysis of the Clinicopathologic Characteristics and Prognosis of Head and Neck Lymphoma
Statistical reports on non-Hodgkinβs lymphoma (NHL) of the head and neck combining clinical medicine with pathology are rare. To provide a basis for prognosis prediction and individualized treatment, we will investigate the clinicopathologic characteristics and prognosis of lymphoma in the head and neck region. Four hundred sixty-one patients with NHL in the head and neck region diagnosed through histological biopsy were retrospectively analyzed. Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) were performed in all cases to evaluate the genetic status and protein expression levels. Patients were followed up by telephone. The prevalence rate of primary extranodal NHL (PENHL) in the head and neck region was 44.62% (166/372). The incidence of extranodal lymphoma accounted for 36.66% (169/461) of all head and neck lymphomas. Among the cases of PENHL of the head and neck, diffuse large B-cell lymphoma (DLBCL) (60/76, 78.95%) and extranodal NK/T-cell lymphoma, nasal type (ENKTCL) (21/24, 87.5%) were the most common subtypes originating from B-cell lymphoma (BCL) and T-cell lymphoma (TCL), respectively. The most common sites of nodal and extranodal onset were neck lymph nodes and the gastrointestinal tract, respectively. The most common and primary locations of BCL and TCL were the tonsils and nasal cavity, respectively. The 3-year survival rates of PENHL, ENKTCL, and DLBCL of the head and neck were 42%, 28.57%, and 41.67%, respectively, and the 5-year survival rates were 24%, 19.05%, and 20%, respectively. Survival analysis showed that male sex was a risk factor ( ; 95% CI, 1.164-25.267; ) and that comprehensive treatment was a protective factor ( ; 95% CI, 0.025-0.545; ) against extranodal DLBCL in the head and neck region. Bone marrow involvement was a risk factor for PENHL of the head and neck ( ; 95% CI, 1.17-21.991; ). The purpose of this review is to show that PENHL of the head and neck with high incidence deserves more attention, and a model of multidisciplinary diagnosis and treatment should be adopted.
- 22 February 2022
- Published byΒ WileyΒ inΒ Analytical Cellular Pathology
- Vol.Β 2022, 1-13
Open AccessAnalysis of the Clinicopathologic Characteristics and Prognosis of Head and Neck Lymphoma
Statistical reports on non-Hodgkinβs lymphoma (NHL) of the head and neck combining clinical medicine with pathology are rare. To provide a basis for prognosis prediction and individualized treatment, we will investigate the clinicopathologic characteristics and prognosis of lymphoma in the head and neck region. Four hundred sixty-one patients with NHL in the head and neck region diagnosed through histological biopsy were retrospectively analyzed. Fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) were performed in all cases to evaluate the genetic status and protein expression levels. Patients were followed up by telephone. The prevalence rate of primary extranodal NHL (PENHL) in the head and neck region was 44.62% (166/372). The incidence of extranodal lymphoma accounted for 36.66% (169/461) of all head and neck lymphomas. Among the cases of PENHL of the head and neck, diffuse large B-cell lymphoma (DLBCL) (60/76, 78.95%) and extranodal NK/T-cell lymphoma, nasal type (ENKTCL) (21/24, 87.5%) were the most common subtypes originating from B-cell lymphoma (BCL) and T-cell lymphoma (TCL), respectively. The most common sites of nodal and extranodal onset were neck lymph nodes and the gastrointestinal tract, respectively. The most common and primary locations of BCL and TCL were the tonsils and nasal cavity, respectively. The 3-year survival rates of PENHL, ENKTCL, and DLBCL of the head and neck were 42%, 28.57%, and 41.67%, respectively, and the 5-year survival rates were 24%, 19.05%, and 20%, respectively. Survival analysis showed that male sex was a risk factor ( ; 95% CI, 1.164-25.267; ) and that comprehensive treatment was a protective factor ( ; 95% CI, 0.025-0.545; ) against extranodal DLBCL in the head and neck region. Bone marrow involvement was a risk factor for PENHL of the head and neck ( ; 95% CI, 1.17-21.991; ). The purpose of this review is to show that PENHL of the head and neck with high incidence deserves more attention, and a model of multidisciplinary diagnosis and treatment should be adopted.
- Open Access
- 28 January 2022
- Published byΒ ElsevierΒ inΒ Pathology - Research and Practice
- Vol.Β 231, 153781
Expression and prognostic analysis of STAT6(YE361) in Hodgkin lymphoma
- 28 January 2022
- Published byΒ ElsevierΒ inΒ Pathology - Research and Practice
- Vol.Β 231, 153781
Open AccessExpression and prognostic analysis of STAT6(YE361) in Hodgkin lymphoma